KNOWLEDGE BANK

Interviews

Exploring New Molecular Targets for Anti-cancer Therapy

Clinical Professor, Department of Medicine, University of British Columbia
Amil Shah is Clinical Professor of Medicine at the University of British Columbia His practice focusses on gastrointestinal and lung cancers Among his administrativeacademic roles he chaired the Gastrointestinal Tumour Group at BC Cancer and served as Associate Dean of the VancouverFraser Medical Program at UBC His research interest is the molecular pathogenesis of cancer

Articles

Why You Might Need a Remediation Program

NSF remediation experts work to assist companies around the world in their remediation efforts Some projects arise from a client identifying a risk themselves while others are a company responding to a communication from a regulatory agency This article will look at why remediation projects are needed the traits of successful programs and what you need to do to ensure success in your remediation e...

Research Insights

SARS-CoV-2 Variant Introduction Following Spring Break Travel and Transmission Mitigation Strategies

In the spring of surging SARSCoV cases kept most universities from inperson education and adversely impacted the learning experience of college students Implementation of a salivabased RTqPCR testing strategy

Case Studies

<sup>14</sup>C microtracer+Accelerator Mass Spectrometry - Xceleron Case Studies

Introduction Xceleron is a world leader in the use of Accelerator Mass Spectrometry AMS analytical technology in pharmaceutical food technology crop protection and biobased product applications Our primary business is in pharmaceutical research and development Since we have been helping to design preclinical and clinical investigations around the

Techno Trends

Breakthrough Biology-Guided Radiotherapy* (BgRT) Discovered for the Treatment of Lung Tumors

RefleXion Medical Inc discovered breakthrough biologyguided radiotherapy BgRTfor the treatment of lung cancer Biologyguided radiotherapyBgRT the first and only technology has the ability to detect and treat the circulating tumours producing active emissions from each tumour

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Nanotechnology as a Potential Therapeutic Strategy in Breast Cancer Management

Mr. Rahul Pal

Mr. Rahul Pal (Young Scientist), Ass. Prof. Department of Pharmacy, Jagannath University, Jaipur, holds B. Pharm, M. Pharm (Pharmaceutics), and PhD* at Chitkara University. He has authored 50+ publications, 8 textbooks, 12 edited book, secured 38 patents, 3 copyrights, received the Young Researcher Award (2025), and actively contributes as reviewer, editor, and speaker in national and international academic forums.

2

A Structured Review on BCRP-Mediated Multidrug Resistance

Nensi Raytthatha

Nensi Raytthatha Research Scholar, Sigma Institute of Pharmacy, Vadodara. She has published more than 5 research and review papers in reputed journals. She has presented more than 10 posters and have attended national and international conferences.

 

Isha Shah

Isha Shah, Research Scholar, Sigma Institute of Pharmacy, Vadodara. She has published five research and review papers in reputed journals. She has presented more than 10 posters and have attended national and international conferences.

 

Jigar Vyas

Jigar Vyas has more than 16 years of teaching and research experience. He has guided more than 40 PG students and has published more than 50 research and review papers. He has received of IQAC award for quality, performance in teaching and research.

 

3

The Transformative Impact of AI on Regulatory Affairs

Yu Han

Yu Han, DPhil in Engineering Science from the University of Oxford, brings a rich background with experience at manufacturer, global regulatory affairs CRO, and AI sector. Her expertise spans the regulatory landscapes of Asia, the US, and the EU, providing a comprehensive understanding of global pharmaceutical regulations. Passionate about combining AI technology with healthcare, Yu excels in creating innovative engineering tools to advance medical solutions. Her work leverages engineering methodologies to unravel complexities in the medical listing process, streamlining the global product flow.     
 <p>&nbsp;</p>
Email: yu.han@eng.ox.ac.uk

 

4

Perspectives on the Vaccine Industry

Josephine Cheng

As a Senior Consultant in Bioprocessing Strategy at Merck with over 14 years of
international biopharma experience, Josephine Cheng focuses on vaccine and mRNA market segments, where she translates strategies into market initiatives to enable the utilisation of best-in-class technologies and transforms industry insights into sustainable business strategies.
Josephine obtained Bachelor's and Master's degrees in Bio-resource's; Agriculture from the National Taiwan University.

 

5

Novel Claudin Targeted C-terminal Clostridium Perfringens Enterotoxin Conjugated Anticancer Nanotherapeutics

Sushil Y. Raut

Sushil Y. Raut Assistant Professor and Head of Research Promotion Cell, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune. He has over 12 years of teaching and research experience. He has more than 25 research and review publications. He filed 3 Indian patents and over 20 national as well as international presentations in his credits. He is recipient of international research mobility fellowship and other prestigious awards.

 

Tanaji D. Nandgude

Tanaji D. Nandgude, Associate Professor, Dr. D. Y. Patil institute of Pharmaceutical Sciences and Research, Pimpri, Pune. He has 15 years of experience in teaching and research in pharmacy. He has more than 50 research/review papers, more than 60 research paper presentations, 5 book publications and granted projects to his credit. He is recipient of “Young Researcher Award”.

 

press releasesRead more...

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

The Ministry of Health Labour and Welfare in Japan has granted approval for Sarclisa isatuximab subcutaneous SC formulation in combination with approved standardofcare regimens for the treatment of multiple myeloma

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Incyte Biosciences Japan GK today announced that Japans Ministry of Health Labour and Welfare MHLW has approved Minjuvi tafasitamab in combination with lenalidomide for the treatment of adults

Samsung Bioepis and Organon Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada

Samsung Bioepis and Organon a global healthcare company with a deep expertise in biosimilars announced the expansion of their development and commercialization agreement whereby Organon will obtain commercialization

Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs

Chai Discovery the AI company engineering models to discover new molecules today announced that certain Chai Discovery frontier AI model capabilities will be made available to companies participating in the Lilly TuneLab platform

Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise

Charles River Laboratories International Inc NYSE CRL announced a collaboration with Lilly TuneLab a collaborative AIML drug discovery platform created by Eli Lilly and Company Lilly

Cold Chain Technologies Launches CCT Rx Secure to Streamline Specialty Pharmacy Shipments

Cold Chain Technologies has launched CCT Rx Secure a new digital application designed to support specialty pharmacies in making more informed repeatable packout decisions for temperaturesensitive shipments

EventsRead more...

18 - 20

Jun 2026

CCT 2026

Barcelona, Spain

23 - 24

Jun 2026

24 - 25

Jun 2026

6th Edition Drug Safety Symposium 2026

Courtyard by Marriott, Mumbai,...

25 - 26

Jun 2026

07 - 09

Jul 2026

The Pharma India Expo 2026

Bombay Exhibition Centre, Mumb...

07 - 09

Jul 2026

08 - 10

Jul 2026

CPHI SEA 2026

QSNCC, Bangkok, Thailand

09 - 11

Jul 2026

Pharma Pro&Pack Expo 2026

HITEX Exhibition Centre, Hyder...

LATEST NEWSRead more...

Greenstone Biosciences and Intel Partner to Advance AI-Driven Drug Discovery

Greenstone Biosciences Inc has entered into a strategic collaboration with Intel Corporation to accelerate AIenabled drug discovery by combining Greenstones largescale human induced pluripotent stem cell iPSC biobank with Intels advanced AI and computing infrastructure

SK pharmteco Partners with OTXL to Advance Rare Disease Therapies

SK pharmteco has entered into a strategic collaboration with the Orphan Therapeutics Accelerator OTXL to support the development and manufacturing of treatments for rare diseases

Boltz Collaborates with Takeda to Expand Use of Biomolecular AI Models in Drug Discovery

Boltz PBC has announced a collaboration with Takeda to deploy its advanced biomolecular artificial intelligence models and platform across Takedas research organisation

Insilico Reaches First Clinical Milestone for AI-Developed NLRP3 Inhibitor ISM8969

Insilico Medicine has completed firstinhuman dosing in the Phase I clinical study of ISM marking the first clinical milestone in its codevelopment partnership with Hygtia Therapeutics ISM is an orally administered

Biogen to Acquire RayThera to Strengthen Immunology Pipeline

Biogen has entered into a definitive agreement to acquire RayThera Inc a privately held biotechnology company focused on developing smallmolecule therapies for immunological diseases The deal is valued at up to billion

Jazz Pharmaceuticals and AbCellera Partner to Develop Next-Generation T-Cell Engaging Antibodies for Cancer

Jazz Pharmaceuticals and AbCellera have entered into a preclinical research collaboration option and licence agreement to discover and develop nextgeneration Tcell engaging TCE multispecific antibodies for gastrointestinal GI cancers and other solid tumours